A new study of adolescents and young adults (AYAs) with seven common cancers reveals that nearly one in ten patients ...
SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...
Low screening rates and the stigma of smoking mean many patients are diagnosed too late to benefit from treatments, according ...
DelveInsight's Rhabdomyosarcoma Market Insights report includes a comprehensive understanding of current treatment practices, ...
A new report affirms that surgical resection is generally sufficient for pediatric patients with low-risk ...
The global soft tissue sarcoma market is poised for substantial growth from 2024 to 2035, driven by the rising prevalence of this rare, aggressive cancer affecting connective tissues. Key growth ...
The International Soft-Tissue Sarcoma Consortium (INSTRuCT) has issued a new consensus document outlining optimal treatment ...
Novel combination with neoadjuvant eftilagimod alfa (efti) achieves significant 51.5% tumour hyalinization/fibrosis across multiple soft tissue ...
The phase 2 ChonDRAgon study compared ozekibart to placebo in patients with metastatic or unresectable conventional chondrosarcoma who been diagnosed with radiographic progression.
A new study of adolescents and young adults (AYAs) with seven common cancers reveals that nearly one in ten patients ...
No significant toxicities observed in 11 patients included in study; 10 were alive at median follow-up of 2.6 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback